Veru Inc. (NASDAQ:VERU) stock is plummeting on Monday after the company released topline results from the Phase 2b QUALITY clinical study of enobosarm for weight reduction. The study evaluates the ...
There were no increases in gastrointestinal side effects. There is also no evidence of drug-induced liver injury, or increases in obstructive sleep apnea at any dose of enobosarm compared to the ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
--International Study Establishes the Role of Androgen Receptor as a Tumor Suppressor in ER+ Advanced Breast Cancer-- --Preclinical Studies Support Enobosarm’s Novel Mechanism of Action as an AR ...
--Phase 2b QUALITY clinical study topline safety data shows that the enobosarm + semaglutide combination had a positive safety profile compared to semaglutide alone-- --Based on Phase 2b QUALITY trial ...
MIAMI, FL, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic ...
Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The ...
Credit: Getty Images. Enobosarm is an oral, first-in-class, selective androgen receptor agonist. The Food and Drug Administration (FDA) has granted Fast Track designation to enobosarm for the ...
MEMPHIS, Tenn.--(BUSINESS WIRE)--GTx, Inc. (Nasdaq: GTXI) today announced results of its two Phase 3 enobosarm clinical trials, the POWER trials, in patients with non-small cell lung cancer (NSCLC) ...
Veru is a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases. The Company’s drug development ...
Enobosarm Phase 2 Trial for Muscle Wasting and Physical Function in Patients with Cancer Published i
MEMPHIS, Tenn.--(BUSINESS WIRE)-- GTx, Inc. (NAS: GTXI) today announced that the journal, The Lancet Oncology, has published online ahead of its April print edition ...
MEMPHIS, Tenn.--(BUSINESS WIRE)--GTx, Inc. (Nasdaq: GTXI) today announced results of its two Phase 3 enobosarm clinical trials, the POWER trials, in patients with non-small cell lung cancer (NSCLC) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results